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Abstract Serum gamma-glutamyltransferase (GGT) has been linked with the risk of adverse health 
outcomes. We aimed to assess the prospective association of GGT activity with pneumonia risk. Serum 
GGT was measured at baseline in 2,400 middle-aged men. Within-person variability in GGT values was 
corrected for using data from repeat measurements. During a median follow-up of 25.3 years, 409 
pneumonia cases were recorded. The age-adjusted regression dilution ratio of GGT was 0.68 (95% CI: 
0.63-0.73). Gamma-glutamyltransferase was approximately log-linearly associated with pneumonia risk. 
In analysis adjusted for several major pneumonia risk factors, the hazard ratio (95% CI) for pneumonia 
per 1 standard deviation increase in GGT was 1.14 (1.02-1.28). The association was however attenuated 
on additional adjustment for high sensitivity C-reactive protein (hsCRP) 1.08 (0.96-1.22). There is an 
approximately log-linear positive association between GGT activity and future risk of pneumonia in a 
middle-aged male population, which is partly dependent on hsCRP.  
 
Keywords gamma-glutamyltransferase; pneumonia; cohort study 
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Abbreviations 
CI Confidence interval 
COPD Chronic obstructive pulmonary disease 
GGT Gamma-glutamyltransferase 
HR Hazard ratio 
hsCRP High sensitivity C-reactive protein 
IQR Interquartile range 
KIHD Kuopio Ischemic Heart Disease 
SD Standard deviation 
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Introduction 
Pneumonia affects about 450 million people worldwide and causes approximately 4 million deaths 
annually.[1] It is a common cause of death among the young, elderly, and people with comorbid 
conditions.[1] Despite the advent of new effective antimicrobial strategies within the last few decades, 
mortality from pneumonia continues to increase.[2] Pneumonia is also associated with substantial 
morbidity, reduced quality of life, and high healthcare costs.[2] Major risk factors which predispose to 
pneumonia include smoking, excessive alcohol consumption, respiratory conditions such as asthma and 
chronic obstructive pulmonary disease (COPD), and other chronic conditions such as kidney and liver 
disease.[2] Pneumonia constitutes a substantial public health burden and is a preventable health condition. 
Gamma-glutamyltransferase (GGT), commonly used as a marker for excessive alcohol consumption 
[3] and an index of liver injury, has been consistently shown to be positively and independently linked 
with the future risk of adverse vascular and non-vascular outcomes. [4,5]  Gamma-glutamyltransferase is 
a marker of oxidative stress[6] and has pro-inflammatory properties[7] and has been suggested to be 
involved in the pathogenesis of these adverse outcomes via pro-oxidant and inflammatory pathways. 
Emerging evidence suggests that high GGT activity is associated with an increased risk of pulmonary 
dysfunction and COPD.[8] Since inflammatory processes as well as oxidative stress are involved in the 
pathogenesis of pneumonia, we hypothesized that GGT may be linked to the risk of pneumonia. However, 
the relationship between GGT and the risk of pneumonia has not been previously investigated. In this 
context, we aimed to assess the prospective association of serum GGT with risk of pneumonia, using a 
study which comprised a population-based cohort of 2,400 Caucasian men.  
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Methods 
Participants in the current analysis comprised a general population-based sample of 2,422 middle-aged 
men aged 42-61 years who were recruited into the Kuopio Ischemic Heart Disease (KIHD) risk factor 
study. The local ethics committee of the University of Eastern Finland approved the study protocol and all 
study procedures were conducted according to the Declaration of Helsinki. Study design, recruitment 
methods and assessment of risk markers have been described in previous reports.[9-11]  Participants of 
the KIHD study constituted a representative sample of men who were living in the city of Kuopio and its 
surrounding rural communities in eastern Finland. Baseline examinations were conducted between March 
1984 and December 1989. Of 3,433 potentially eligible and randomly selected men who were invited to 
participate in the study, 3,235 were found to be eligible. Of this number, 553 did not respond to the 
invitation or declined to give informed consent, leaving 2,682 men who volunteered to participate in the 
study. The current dataset analyzed comprised of 2,400 men who had complete information on GGT, 
relevant covariates, and pneumonia outcomes. Serum GGT activity was measured using the kinetic 
method (Thermo Fisher Scientific, Vantaa, Finland) with repeat measurements performed 4 years and 11 
years after the baseline measurements in a random subset of participants.[9,10] Incident cases of 
pneumonia that occurred from study entry to 2014 were included in this analysis. The diagnoses of 
pneumonia cases were made by qualified physicians based on the International Classification of Diseases 
codes used in clinical practice and were collected by linkage to the National Hospital Discharge Register 
and a comprehensive review of hospital records. All skewed variables (GGT, high sensitivity C-reactive 
protein (hsCRP), and triglycerides) underwent log transformation to approximate normal distributions. 
Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazard 
models. All statistical analyses were conducted using Stata version 14 (Stata Corp, College Station, 
Texas). 
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Results 
Baseline characteristics of study participants and cross-sectional correlates of GGT are reported in Table 
1. The mean [standard deviation (SD)] age of study subjects at study entry was 53 (5) years. The mean 
(SD) of loge GGT was 3.13 (0.65) U/L. Serum GGT values were significantly and positively correlated 
with alcohol consumption, physical measures [body mass index (BMI) and blood pressure], lipids, fasting 
plasma glucose, and inflammation as measured by hsCRP.  
During a median (IQR) follow-up of 25.3 (16.8-27.8) years, 409 hospital diagnosed pneumonia cases 
were recorded (incident rate of 7.84 per 1000 person-years at risk; 95% CI 7.12 to 8.64). Repeat 
measurements of GGT taken 4 and 11 years after baseline were available in a random sample of 730 men. 
The overall age-adjusted regression dilution ratio of GGT was 0.68 (95% CI: 0.63 to 0.73), which 
suggests that using baseline measurements of GGT could underestimate the association between GGT and 
pneumonia risk by [(1/0.68)-1]*100 = 47%. On adjustment for risk factors for pneumonia (age, BMI, 
smoking status, history of diabetes, prevalent histories of coronary heart disease, asthma, chronic 
bronchitis, tuberculosis and cancer, alcohol consumption, socioeconomic status, and physical activity), 
GGT was positively associated with the risk of pneumonia in an approximately log-linear fashion 
(Figure). In an age-adjusted analysis, the HR for pneumonia per 1 SD increase in GGT was 1.17 (95% 
CI: 1.05 to 1.29), which was minimally attenuated on further adjustment for several risk factors for 
pneumonia 1.14 (95% CI: 1.02 to 1.28). The association was attenuated on additional adjustment for 
hsCRP 1.08 (95% CI: 0.96 to 1.22). The associations were stronger after correction for within-person 
variability in GGT values (Table). In an age-adjusted analysis, the initial association 1.17 (95% CI: 1.05 
to 1.29) was attenuated after single additional adjustment for hsCRP 1.06 (95% CI, 0.95 to 1.18). 
 
Discussion 
In this general population-based cohort of middle-aged approximately healthy Caucasian men, we 
observed an increase in the risk of pneumonia with increasing GGT activity. The association between 
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GGT activity and pneumonia remained independent after adjustment for several established risk factors, 
but was attenuated on further adjustment for hsCRP. Additionally, in an age-adjusted analysis, the GGT-
pneumonia association was attenuated on single additional adjustment for hsCRP; which suggest that the 
association between GGT and pneumonia is dependent on inflammation. Pneumonia is a well-known 
inflammatory condition of the lung tissue,[12] oxidative stress is a common pathogenic mechanism 
underlying the development of inflammatory lung diseases such as pneumonia,[13] and high GGT 
activity signifies a state of oxidative stress.[14] Elevated GGT activity may also reflect chronic 
subclinical inflammation, a state characterised by elevated levels of CRP, which is also secreted by the 
liver and directly and strongly correlated with GGT activity.[15] Taking the evidence together suggests 
that inflammatory processes and oxidative stress may underlie the aetiology between GGT and 
pneumonia. However, it is unlikely that high GGT activity can be considered a direct cause of pneumonia 
on the basis of current evidence, but rather GGT is a risk marker of pneumonia. It can also be argued that 
high GGT activity is a marker of underlying health status such as poor general health due to a disease 
condition, which may predispose to pneumonia. Furthermore, increased GGT activity is a biomarker of 
exposure to smoking and various environmental pollutants,[16,17] which may play direct roles in the 
aetiogenesis of pneumonia. Despite the likelihood that GGT could only be a risk marker for pneumonia, 
assays for GGT may have the potential to aid in the identification of individuals at high risk of developing 
pneumonia. There is already accumulating evidence that elevated GGT activity (even below the upper 
limits of normal) is associated with an increased risk of several chronic disease conditions.[4] Assays for 
GGT are commonly measured as part of routine liver function panels and are sensitive, well standardized, 
inexpensive, and simple tests. Further investigation into the biological pathways involved in the 
relationship between GGT and pneumonia and whether information on GGT can be used in risk 
assessment of pneumonia is warranted. 
This is the first evaluation of the association between serum GGT activity and the risk of prospectively 
collected pneumonia cases using a general population-based prospective cohort study. Other strengths 
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include the large sample size, long-term and complete follow-up of participants, and detailed analyses 
which include adjustment for a comprehensive panel of major confounders, assessment of the shape of the 
relationship between GGT and pneumonia risk, as well as correction for within-person variability in GGT 
values. A number of limitations deserve mention and which include (i) the inability to generalize the 
findings to women and other races; (ii) lack of data on other liver enzymes, hence the inability to assess 
for confounding or interaction; (iii) the possibility of residual confounding due to errors in measurements 
of some covariates and/or unmeasured relevant confounders such as underlying health conditions (eg. 
autoimmune diseases, viral hepatitis, cholelithiasis), influenza immunisation status, lung function, and 
other health modifying behaviours; and (iv) biases due to lack of data on specific types of pneumonia and 
possibility of excluding potential cases of pneumonia that were not captured at healthcare facilities. 
In conclusion, there is an approximately log-linear positive association between GGT activity and 
future risk of pneumonia in a middle-aged population, which is partly dependent on inflammation as 
measured by hsCRP. Further research is needed to evaluate if measurements of GGT will have any role in 
the prevention and risk assessment of pneumonia in the general population. 
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Figure legend 
 
Figure. Hazard ratios for pneumonia, by quartiles of baseline levels of gamma-glutamyltransferase 
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A, adjusted for age; B, adjusted for age, body mass index, smoking status, history of diabetes, prevalent 
coronary heart disease, history of asthma, history of chronic bronchitis, history of tuberculosis, history of 
cancer, alcohol consumption, socioeconomic status, and physical activity 
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Table 1. Baseline characteristics and cross-sectional correlates of gamma-glutamyltransferase 
 Mean (SD) or median (IQR) 
or n (%) 
Pearson correlation 
r (95% CI)† 
GGT (U/L) 20 (15-33) - 
   
Questionnaire/Prevalent conditions   
Age at survey (years) 53 (5) -0.03 (-0.07, 0.01) 
Alcohol consumption (g/week) 75.1 (134.3) 0.29 (0.25, 0.32)*** 
History of type 2 diabetes 98 (4.1) - 
Current smoker 764 (31.8) - 
History of CHD 615 (25.6) - 
History of asthma 84 (3.5) - 
History of chronic bronchitis 181 (7.5) - 
History of tuberculosis 93 (3.9) - 
History of cancer 41 (1.7) - 
   
Physical measurements   
BMI (kg/m2) 26.9 (3.6) 0.34 (0.31, 0.38)*** 
SBP (mmHg) 134 (17) 0.22 (0.18, 0.26)*** 
DBP (mmHg) 89 (11) 0.23 (0.19, 0.26)*** 
Physical activity (KJ/day) 1538 (1483) 0.03 (-0.01, 0.07) 
Socio-economic status 8.57 (4.22) 0.01 (-0.03, 0.05) 
   
Lipid markers   
Total cholesterol (mmol/l) 5.91 (1.09) 0.10 (0.06, 0.14)*** 
HDL-C (mmol/l) 1.30 (0.30) -0.03 (-0.07, 0.01) 
Triglycerides (mmol/l) 1.10 (0.80-1.56) 0.26 (0.23, 0.30)*** 
   
Metabolic, renal, and inflammatory markers   
Fasting plasma glucose (mmol/l) 5.36 (1.28) 0.20 (0.16, 0.24)*** 
Serum creatinine (µmol/1) 89.6 (20.8) 0.00 (-0.04, 0.04) 
Estimated GFR (ml/min/1.73 m2) 87.0 (17.2) -0.00 (-0.04, 0.04) 
C-reactive protein (mg/l) 1.30 (0.71-2.49) 0.26 (0.23, 0.30)*** 
 
 BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol;  
SD, standard deviation; SBP, systolic blood pressure; asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001, 
†Pearson correlation coefficients between loge GGT and the row variables adjusted for age  
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Table 2. Association between gamma-glutamyltransferase and risk of pneumonia 
GGT (U/L) Model 1  Model 2  Model 3  
 HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Baseline GGT 1.17 (1.05 to 1.29) 0.004 1.14 (1.02 to 1.28) 0.026 1.08 (0.96 to 1.22) 0.175 
Usual GGT* 1.25 (1.08 to 1.46) 0.004 1.21 (1.02 to 1.44) 0.026 1.13 (0.95 to 1.34) 0.175 
 
HRs are reported per SD increase in GGT values 
CI, confidence interval; GGT, gamma-glutamyltransferase; HR, hazard ratio; SD, standard deviation;  
*, indicates correction for within-person variability in values of GGT, that is, the extent to which an individual’s GGT 
measurements vary around a long-term average value (“usual GGT values”) 
Model 1: Adjusted for age  
Model 2: Model 1 plus body mass index, smoking status, history of diabetes, prevalent coronary heart disease, history of asthma, 
history of chronic bronchitis, history of tuberculosis, history of cancer, alcohol consumption, socioeconomic status, and physical 
activity 
Model 3: Model 2 plus high sensitivity C-reactive protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
